导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.04% | 3978/4773 |
| 近一周 | -1.93% | 905/5462 |
| 近一月 | -1.34% | 919/5421 |
| 近一季 | 0.70% | 647/5209 |
| 近半年 | -9.59% | 3519/4920 |
| 近一年 | -17.61% | 3845/4366 |
| 近两年 | 6.90% | 2826/2954 |
| 近三年 | -11.11% | 2048/2253 |
| 成立以来 | 26.48% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.63% 4241/4961 |
-11.06% 4229/5312 |
- - |
- - |
| 2025 | 0.30% 3272/4813 |
-1.07% 2571/3635 |
-3.27% 3422/4076 |
10.38% 3298/4524 |
-5.04% 3506/4813 |
| 2024 | 8.16% 1584/3463 |
3.57% 541/2808 |
-6.42% 1940/3014 |
18.65% 969/3129 |
-5.95% 2613/3463 |
| 2023 | -12.08% 1446/2656 |
1.58% 1547/2280 |
-6.92% 1741/2385 |
-1.50% 532/2515 |
-5.59% 1407/2655 |
| 2022 | -16.44% 481/2207 |
-19.49% 1465/1919 |
17.65% 121/2016 |
-12.57% 729/2113 |
0.90% 1435/2208 |
| 2021 | -10.25% 1094/1822 |
-2.70% 692/1255 |
1.44% 1052/1330 |
-12.20% 1296/1466 |
3.57% 420/1822 |
| 2020 | - - |
- - |
- - |
23.74% 28/1164 |
22.33% 47/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华宝中证消费龙头指数(LOF)C VS. 长安沪深300非周期A(740101) |